会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Naphthyridinium derivatives
    • 萘吡啶衍生物
    • US5686251A
    • 1997-11-11
    • US510316
    • 1995-08-02
    • Seikoh HoriuchiKazuharu IenagaKo Nakamura
    • Seikoh HoriuchiKazuharu IenagaKo Nakamura
    • G01N33/531C07D471/04C07K14/76C07K16/00C07K16/44G01N33/53G01N33/532G01N33/68
    • G01N33/6842C07D471/04C07K16/44G01N33/5308G01N33/68Y02P20/55
    • The present invention provides naphthyridinium derivatives which are effective, for example, in diagnosis of diabetes, diabetic complications, dialysis-related complications, aging, diseases accompanied by aging, etc. and also provides an antibody prepared from said derivative as a hapten. The naphthyridinium derivatives of the present invention are compounds represented by the general formula (I): ##STR1## wherein R and R' may be the same or different and are alkyl groups optionally substituted with at least one amino group, at least one protected amino group, at least one carboxyl group, or combinations thereof, and their pharmaceutically accepted salts. It is possible to conduct the diagnosis of diabetes, diabetic complications, dialysis-related complications, aging, diseases accompanied by aging, etc. using a compound of the present invention as an indicator. Moreover, it is possible to utilize a compound of the present invention for the evaluation of the pharmaceutical effect of pharmaceuticals effective for treating diabetes-related diseases, dialysis-related complications, aging and diseases accompanied by aging.
    • 本发明提供了例如糖尿病诊断,糖尿病并发症,透析相关并发症,衰老,老化等疾病等有效的萘啶鎓衍生物,并且还提供由所述衍生物制备的抗体作为半抗原。 本发明的萘啶鎓衍生物是由通式(I)表示的化合物:其中R和R'可以相同或不同,并且是任选被至少一个氨基取代的烷基,至少 一个保护的氨基,至少一个羧基或其组合,以及它们的药学上可接受的盐。 使用本发明化合物作为指标,可以进行糖尿病,糖尿病并发症,透析相关并发症,老化,老化等疾病的诊断。 此外,可以利用本发明的化合物来评价有效治疗糖尿病相关疾病,透析相关并发症,老化和伴随衰老的疾病的药物的药效。
    • 5. 发明授权
    • Acylindole derivatives and their use in pharmaceutical compositions
    • 丁醛衍生物及其在药物组合物中的应用
    • US4708961A
    • 1987-11-24
    • US919746
    • 1986-10-16
    • Kazuharu IenagaKo Nakamura
    • Kazuharu IenagaKo Nakamura
    • C07D209/12A61K31/40
    • C07D209/12
    • The present invention is concerned with novel acylindole derivatives of the formula (I) and platelet-aggregation inhibiting agents containing them as an active ingredient. ##STR1## In the formula (I), either R.sub.1 and R.sub.2 is hydrogen, an alkyl group having 1 to 5 carbon atoms, an alkyl group substituted by at least one hydroxy group and having 1 to 5 carbon atoms, or a group of the formula ##STR2## in which R.sub.3 is an alkyl group having 1 to 5 carbon atoms, and --OR.sub.2 is a substituent at the ortho or para position.The compounds of the invention are useful as preventive medicine or remedy for various diseases or symptoms caused by platelet-aggregation, as well as inhibitors of platelet-aggregation on vascular walls during or after an operation.
    • 本发明涉及式(I)的新型丙烯酰基吲哚衍生物和含有它们作为活性成分的血小板聚集抑制剂。 (I)在式(I)中,R 1和R 2是氢,具有1至5个碳原子的烷基,被至少一个羟基取代且具有1至5个碳原子的烷基,或 其中R 3是具有1至5个碳原子的烷基的式“IMAGE”的基团,-OR 2是邻位或对位的取代基。 本发明的化合物可用作预防药物或由血小板聚集引起的各种疾病或症状的补救剂,以及在手术期间或手术后在血管壁上血小板聚集的抑制剂。
    • 8. 发明授权
    • Hypoglycemic hydantoin derivatives
    • 低血糖乙内酰脲衍生物
    • US4647574A
    • 1987-03-03
    • US709861
    • 1985-03-08
    • Kazuharu IenagaKo Nakamura
    • Kazuharu IenagaKo Nakamura
    • C07D233/66C07D233/72C07D233/74A61K31/415
    • C07D233/72
    • The present invention relates to novel hydantoin derivatives represented by the general formula (I) and pharmaceutical compositions containing them as an active ingredient. ##STR1## In the formula (I), X is hydrogen or a group having the formula --OR.sub.4, and each of R.sub.1, R.sub.2, R.sub.3 and R.sub.4, which may be the same or different, is hydrogen, an alkyl group or a cycloalkyl group.Hydantoin derivatives and pharmaceutically acceptable salts thereof of the present invention have excellent hypoglycemic, hypolipidemic and diuretic effects, as well as low toxicity and great safety. Therefore, the compounds of the present invention are not only useful as antidiabetics but also as drugs for hyperlipidemia.
    • 本发明涉及由通式(I)表示的新型乙内酰脲衍生物和含有它们作为有效成分的药物组合物。 (I)在式(I)中,X是氢或具有式-OR 4的基团,R 1,R 2,R 3和R 4可以相同或不同,为氢,烷基 或环烷基。 本发明的乙内酰脲衍生物及其药学上可接受的盐具有优异的降血糖,降血脂和利尿作用,并且毒性低,安全性高。 因此,本发明的化合物不仅可用作抗糖尿病药,还可用作高脂血症药物。
    • 10. 发明授权
    • Agent for hypoalbuminaemia
    • 低白蛋白血症的代理
    • US06451831B1
    • 2002-09-17
    • US10074772
    • 2002-02-12
    • Kazuharu IenagaHiroki MikamiRyoji Nishibata
    • Kazuharu IenagaHiroki MikamiRyoji Nishibata
    • A61K31415
    • A61K31/4166
    • A highly safe and useful therapeutic agent for hypoalbuminaemia contains a hydantoin derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof as an effective ingredient: wherein each of R1 and R2, which may be the same or different, represents hydrogen, an alkyl group or a cycloalkyl group; and each of X and Y, which may be the same or different, represents hydrogen, a hydroxyl group, an alkyl group or an alkoxy group, or X and Y together represent an oxo group. Administration of the compounds substantially increases the serum albumin value of patients suffering from hypoalbuminaemia from abnormal values, and significantly improves the condition of hypoalbuminaemia.
    • 用于低白蛋白血症的高度安全和有用的治疗剂含有由式(I)表示的乙内酰脲衍生物或其药学上可接受的盐作为有效成分:其中R 1和R 2可以相同或不同,表示氢, 烷基或环烷基; X和Y各自可以相同或不同,表示氢,羟基,烷基或烷氧基,或X和Y一起表示氧代基。 化合物的施用显着提高了患有低蛋白血症的患者的血清白蛋白值异常值,并显着改善了低白蛋白血症的状况。